Andy C.

About

Specialties: Business development, scientific and commercial assessment of biotech/pharmaceutical assets, biotech investment, corporate strategy, growth strategy, management consulting, venture capital, drug development Scientific expertise: Oncology, metabolism, immunology, vaccines, infectious diseases, and personalized medicine

Experience

• Portfolio Manager, Therapeutics at Longaeva Partners LP
  Jun 2025 - Present · 1 yr 1 mo

• Therapeutics investment at Citadel
  Mar 2020 - May 2025 · 5 yrs 3 mos

  Jan 2021-May 2025 - Analyst March 2020-Dec 2020 - Senior Associate Analyst

• Sr. Director, Business Development at CytomX Therapeutics
  May 2019 - Mar 2020 · 11 mos

  *In-licensed CX-2051 from Immunogen (EpCAM Probody) (led diligence, deal lead, negotiated terms and contract) *Licensing agreement with Astellas for bispecific probody programs (member of deal team, negotiated terms and contract)

• Therapeutics investment at Citadel
  Feb 2018 - Apr 2019 · 1 yr 3 mos

  Associate Analyst Long-Short, market neutral hedge fund. Covered SMID therapeutics companies, including those in Oncology, inflammation, liver disease, and spec. pharma.

• Equity Research at AB Bernstein
  Jan 2017 - Dec 2017 · 1 yr

  Covered large cap biotech and specialty pharma (Ronny Gal, senior analyst)